Profile
Roland Wandeler is President-Biopharma Business Unit at Grifols SA since 2024.
Former roles include Chief Executive Officer at Sundance Biosciences, Inc. from 2022 to 2023, VP, GM-US Bone Health & Cardiology Business Unit at Amgen, Inc., and Chief Operating Officer at MorphoSys AG from 2020 to 2021.
Education includes graduate and doctorate degrees from the Swiss Federal Institute of Technology.
Roland Wandeler active positions
| Companies | Position | Start |
|---|---|---|
| GRIFOLS, S.A. | Corporate Officer/Principal | 31/12/2023 |
Former positions of Roland Wandeler
| Companies | Position | End |
|---|---|---|
Encinal Bio, Inc. | Chief Executive Officer | 30/09/2023 |
| MORPHOSYS AG | Chief Operating Officer | 30/12/2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Training of Roland Wandeler
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Grifols SA
Grifols SA Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceuticals, diagnostic and bio supplies | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Encinal Bio, Inc. |
- Stock Market
- Insiders
- Roland Wandeler
















